Stephen Harper

Title: The Innovative Contributions of Stephen Harper

Introduction

Stephen Harper is a notable inventor based in Abingdon, GB, recognized for his significant contributions to the field of immunotherapy. With a total of four patents to his name, Harper has made strides in developing novel treatments for malignant diseases.

Latest Patents

Harper's latest patents include groundbreaking inventions related to binding molecules and T cell receptors. The first patent focuses on binding molecules that comprise T cell receptor (TCR) variable domains, which can bind to a PIWIL1 peptide-HLA complex. This invention holds promise for the treatment of malignant diseases. The second patent pertains to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL, derived from the germline cancer antigen PRAME. These TCRs may include non-natural mutations within the alpha and/or beta variable domains, making them particularly suitable as novel immunotherapeutic reagents for treating malignant diseases.

Career Highlights

Stephen Harper is currently associated with Immunocore Limited, a company that focuses on developing innovative therapies for cancer treatment. His work has been instrumental in advancing the understanding and application of T cell receptors in immunotherapy.

Collaborations

Harper collaborates with esteemed colleagues such as Nathaniel Ross Liddy and Philip William Addis, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Stephen Harper's inventive work in the field of immunotherapy exemplifies the impact of innovative thinking on medical science. His patents and collaborations continue to pave the way for advancements in the treatment of malignant diseases.